Evidence map›Paper›PMID 37480459›Full record

ReviewAdvances in neurobiology2023

Nanodelivery of Histamine H3/H4 Receptor Modulators BF-2649 and Clobenpropit with Antibodies to Amyloid Beta Peptide in Combination with Alpha Synuclein Reduces Brain Pathology in Parkinson's Disease.

Anca D Buzoianu, Aruna Sharma, Dafin F Muresanu, Lianyuan Feng, Hongyun Huang, Lin Chen, Z Ryan Tian, Ala Nozari, José Vicente Lafuente, Lars Wiklund and 1 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Advances in neurobiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 8 institutions in 5 countries.

Anca D BuzoianuDepartment of Clinical Pharmacology and Toxicology, "Iuliu Hatieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania.
Aruna SharmaInternational Experimental Central Nervous System Injury & Repair (IECNSIR), Department of Surgical Sciences, Anesthesiology & Intensive Care Medicine, Uppsala University Hospital, Uppsala University, Uppsala, Sweden.
Dafin F MuresanuDepartment of Clinical Neurosciences, University of Medicine & Pharmacy, Cluj-Napoca, Romania.
Lianyuan FengDepartment of Neurology, Bethune International Peace Hospital, Zhongshan, Hebei Province, China.
Hongyun HuangBeijing Hongtianji Neuroscience Academy, Beijing, China.
Lin ChenDepartment of Neurosurgery, Dongzhimen Hospital, Beijing University of Traditional Chinese Medicine, Beijing, China.
Z Ryan TianDepartment of Chemistry & Biochemistry, University of Arkansas, Fayetteville, AR, USA.
Ala NozariAnesthesiology & Intensive Care, Chobanian & Avedisian School of Medicine, Boston University, Boston, MA, USA.
José Vicente LafuenteLaNCE, Department of Neuroscience, University of the Basque Country (UPV/EHU), Leioa, Bizkaia, Spain.
Lars WiklundInternational Experimental Central Nervous System Injury & Repair (IECNSIR), Department of Surgical Sciences, Anesthesiology & Intensive Care Medicine, Uppsala University Hospital, Uppsala University, Uppsala, Sweden.
Hari Shanker SharmaInternational Experimental Central Nervous System Injury & Repair (IECNSIR), Department of Surgical Sciences, Anesthesiology & Intensive Care Medicine, Uppsala University Hospital, Uppsala University, Uppsala, Sweden. Sharma@surgsci.uu.se.
Uppsala University Hospital · SEBethune International Peace Hospital · CNBoston University · USDongzhimen Hospital Affiliated to Beijing University of Chinese Medicine · CNIuliu Hațieganu University of Medicine and Pharmacy · ROUniversity of Agricultural Sciences and Veterinary Medicine of Cluj-Napoca · ROUniversity of Arkansas at Fayetteville · USUniversity of the Basque Country · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Parkinson's disease (PD) in military personnel engaged in combat operations is likely to develop in their later lives. In order to enhance the quality of lives of PD patients, exploration of novel therapy based on new research strategies is highly warranted. The hallmarks of PD include increased alpha synuclein (ASNC) and phosphorylated tau (p-tau) in the cerebrospinal fluid (CSF) leading to brain pathology. In addition, there are evidences showing increased histaminergic nerve fibers in substantia niagra pars compacta (SNpc), striatum (STr), and caudate putamen (CP) associated with upregulation of histamine H3 receptors and downregulation of H4 receptors in human brain. Previous studies from our group showed that modulation of potent histaminergic H3 receptor inverse agonist BF-2549 or clobenpropit (CLBPT) partial histamine H4 agonist with H3 receptor antagonist induces neuroprotection in PD brain pathology. Recent studies show that PD also enhances amyloid beta peptide (AβP) depositions in brain. Keeping these views in consideration in this review, nanowired delivery of monoclonal antibodies to AβP together with ASNC and H3/H4 modulator drugs on PD brain pathology is discussed based on our own observations. Our investigation shows that TiO

Indexed as

Parkinson DiseaseReceptors, Histamine H3alpha-SynucleinAmyloid beta-PeptidesAntibodies, MonoclonalBrainDrug Inverse AgonismHistamineHumansImidazolesNanoparticle Drug Delivery SystemReceptors, Histamine H4Thioureaalpha-SynucleinAmyloid beta-PeptidesAntibodies, MonoclonalclobenpropitHistamineImidazolesNanoparticle Drug Delivery SystemReceptors, Histamine H3Receptors, Histamine H4ThioureaAlpha synucleinAmyloid beta peptideBF-2549Brain pathologyClobenpropitDopamineHistamineNeuroprotectionParkinson’s diseasePhosphorylated tau

Identifiers

PMID37480459
OpenAlexW4385146576

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.